Using a mobile app to help young people with HIV achieve viral suppression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of the Positive Peers mobile app in improving viral suppression rates among young individuals aged 13 to 34 who are living with HIV. Participants will download the app and use it as they find beneficial, while also completing online surveys at various intervals over a year. The study aims to identify user characteristics that correlate with viral suppression, retention in care, and perceived stigma related to HIV. Data will be collected from both the app usage and medical records to assess the intervention's impact.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* HIV+
* Identifies as either a racial, ethnic, sexual or gender minority or a cisgender female and

One of the following:

* Newly diagnosed within last 12 months
* Out of care (greater than 6 months between any two HIV provider visits in last 24 months)
* Not virally suppressed (any viral load \> 200 copies in last 24 months)
* Has a working smartphone
* Functional English ability

Exclusion Criteria:

* prior use of Positive Peers mobile app

Where it's running

• Northeast Valley Health Corporation
  Van Nuys, California, United States Recruiting
• Infectious Disease Practice- Rutgers University
  Newark, New Jersey, United States Recruiting
• Equitas Health
  Cincinnati, Ohio, United States Recruiting
• St. Jude Children's Research Hospital
  Memphis, Tennessee, United States Recruiting
• Thomas Street Clinic
  Houston, Texas, United States Recruiting
• UW Madison Clinic at Harborview
  Seattle, Washington, United States Recruiting

Study contacts

• Principal investigator: Ann Avery, MD — MetroHealth/ CWRU
• Study coordinator: Jennifer McMillen-Smith, LISW-S
• Email: jmsmith@metrohealth.org
• Phone: 2167784051

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Camino HIV Prevention and Care Study

  This study tests a combined legal and peer-support program to help Latin American adults in DC and the Bay Area improve HIV testing, PrEP use, and care engagement.

  Recruiting American University · Berkeley, California and 1 other locations · NCT07834853

• VH4367310 in healthy adults: testing single increasing doses for safety and how it behaves in the body

  This study tests a single rising dose of VH4367310, a cabotegravir prodrug, to see how it behaves in the body and how safe and tolerable it is in healthy adults aged 18 to 55.

  Recruiting at 2 sites Phase 1 ViiV Healthcare · Glendale, California and 1 other locations · NCT07818915

• Online cohort of sexual and gender minorities testing digital support to boost PrEP and ART use

  In Brazil, sexually and gender diverse adults are being followed online to see if weekly WhatsApp reminders help people stick to PrEP or ART.

  Recruiting Oswaldo Cruz Foundation · Rio de Janeiro, Rio de Janeiro · NCT07772791

• Metabolic Liver Disease in People Newly Diagnosed with HIV

  This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.

  Recruiting at 11 sites Guven Health Group · Ankara, Ankara and 10 other locations · NCT07737340

• Screen2Prevent: HIV screening for teens and young adults in emergency departments

  The study tests three ways of offering HIV screening to people aged 14–24 in emergency departments to see if it helps link them to PrEP or HIV treatment using digital health tools.

  Recruiting at 5 sites Westat · Tampa, Florida and 4 other locations · NCT07728123

• Long-acting LEN/TAB/ZAB vs CAB/RPV in adults with HIV-1 who are virologically suppressed on daily ART

  This study tests whether switching to a weekly-plus long-acting injectable regimen of lenacapavir, teropavimab, and zinlirvimab works as well as a two-drug injectable regimen of cabotegravir and rilpivirine for adults with HIV-1 who already have undetectable virus on daily treatment.

  Recruiting at 19 sites Phase 3 Gilead Sciences · San Francisco, California and 18 other locations · NCT07682961

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.